Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68,425 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
de Bruyn G, Wang J, Purvis A, Ruiz MS, Adhikarla H, Alvi S, Bonaparte MI, Brune D, Bueso A, Canter RM, Ceregido MA, Deshmukh S, Diemert D, Finn A, Forrat R, Fu B, Gallais J, Griffin P, Grillet MH, Haney O, Henderson JA, Koutsoukos M, Launay O, Torres FM, Masotti R, Michael NL, Park J, Rivera-Medina DM, Romanyak N, Rook C, Schuerman L, Sher LD, Tavares-Da-Silva F, Whittington A, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00002 booster cohorts study team. de Bruyn G, et al. Among authors: park j. EClinicalMedicine. 2023 Jul 22;62:102109. doi: 10.1016/j.eclinm.2023.102109. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37533419 Free PMC article.
Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series.
Park J, Archuleta S, Oh MH, Shek LP, Jin J, Bonaparte M, Fargo C, Bouckenooghe A. Park J, et al. Hum Vaccin Immunother. 2020 Mar 3;16(3):523-529. doi: 10.1080/21645515.2019.1661204. Epub 2019 Nov 5. Hum Vaccin Immunother. 2020. PMID: 31464558 Free PMC article. Clinical Trial.
Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.
Park J, Archuleta S, Oh MH, Shek LP, Wang H, Bonaparte M, Frago C, Bouckenooghe A, Jantet-Blaudez F, Begue S, Gimenez-Fourage S, Pagnon A. Park J, et al. Hum Vaccin Immunother. 2021 Jul 3;17(7):2107-2116. doi: 10.1080/21645515.2020.1861875. Epub 2021 Feb 24. Hum Vaccin Immunother. 2021. PMID: 33626291 Free PMC article. Clinical Trial.
Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
Coronel-MartÍnez DL, Park J, López-Medina E, Capeding MR, Cadena Bonfanti AA, Montalbán MC, Ramírez I, Gonzales MLA, DiazGranados CA, Zambrano B, Dayan G, Savarino S, Chen Z, Wang H, Sun S, Bonaparte M, Rojas A, Ramírez JC, Verdan MA, Noriega F. Coronel-MartÍnez DL, et al. Among authors: park j. Lancet Infect Dis. 2021 Apr;21(4):517-528. doi: 10.1016/S1473-3099(20)30767-2. Epub 2020 Nov 16. Lancet Infect Dis. 2021. PMID: 33212067 Clinical Trial.
Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
Coronel-Martinez DL, Park J, López-Medina E, Capeding MR, Bonfanti AAC, Montalbán MC, Ramírez I, Gonzales MLA, Zambrano B, Dayan G, Chen Z, Wang H, Bonaparte M, Rojas A, Ramírez JC, Verdan MA, Noriega F. Coronel-Martinez DL, et al. Among authors: park j. Lancet Infect Dis. 2022 Jun;22(6):901-911. doi: 10.1016/S1473-3099(21)00706-4. Epub 2022 Mar 29. Lancet Infect Dis. 2022. PMID: 35364022 Clinical Trial.
Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies.
Liu X, Park J, Xia S, Liang B, Yang S, Wang Y, Syrkina O, Lavis N, Liu S, Zhao C, Ding J, Hu J, Samson SI, de Bruijn IA; FSQ01 and FSQ02 Study Groups. Liu X, et al. Among authors: park j. Hum Vaccin Immunother. 2022 Nov 30;18(6):2132798. doi: 10.1080/21645515.2022.2132798. Epub 2022 Nov 3. Hum Vaccin Immunother. 2022. PMID: 36328438 Free PMC article. Clinical Trial.
Matched vs Nonmatched Placebos in a Randomized Trial of COVID-19 Treatments.
Reis G, Savassi LCM, Ferreira TS, Reis LLF, Simplicio MIC, Ribeiro LB, Silva EADSM, Lat PK, Harari O, Forrest JI, Dron L, Park JJH, Thorlund K, Mills EJ. Reis G, et al. Among authors: park jjh. JAMA Netw Open. 2024 May 1;7(5):e2410335. doi: 10.1001/jamanetworkopen.2024.10335. JAMA Netw Open. 2024. PMID: 38767921 Clinical Trial.
68,425 results
You have reached the last available page of results. Please see the User Guide for more information.